Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

This study has been completed.
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: December 26, 2007
Last updated: September 26, 2011
Last verified: September 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2010
  Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)